Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Microsulis: Firm will use $45 mil. round financing to hire 50 direct sales reps/physician educators to support full launch of Microwave Endometrial Ablation (MEA) system to treat menorrhagia. Approved last September, MEA has been slowly rolled out, awaiting funding for clinical specialists required under FDA clearance (1"The Gray Sheet" Oct. 20, 2003, In Brief). Microsulis currently is evaluating distributors for metropolitan areas. The funds also will go to support separate 510(k) applications for soft tissue ablation and peripheral vascular indications to be submitted by year-end. Existing investors contributed $20 mil. to the round, while the remaining $25 mil. came from venture capital...
You may also be interested in...
NuVasive IPO: Minimally Invasive Spine Firm Offers Up To $92 Mil. In Stock
NuVasive plans to use proceeds from its initial public offering to develop injectable disc nucleus replacement materials and total lumbar disc products
Angiodynamics To Realize Independence From E-Z-Em Through IPO
Angiodynamics asserts that its focus on peripheral vascular disease (PVD) and its broad product line will enable the firm to hold its own against larger competitors once it goes public
Animas IPO: Insulin Pump Maker Offers Up To $69 Mil. In Stock
Proceeds from Animas Corp.'s initial public offering will support sales and marketing of the IR 1200 third-generation insulin pump and evaluation of continuous glucose sensor technology licensed from Thomas Jefferson University, the manufacturer notes